Morgan Stanley analyst Sean Laaman upgrades ResMed (NYSE:RMD) from Equal-Weight to Overweight and announces $169price target.A great result - treated like ..Copyright © Benzinga. All rights reserved. Write to [email protected] with any questions about this content. Benzinga does not provide investment advice.
© 2023 Benzinga Newswires. Benzinga does not provide investment advice. All rights reserve
5% layoff. Margins will see better days
lets have some RMD..
First Quarter (23/24) Results, page-31
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$29.90 |
Change
1.250(4.36%) |
Mkt cap ! $18.94B | |||
| Open | High | Low | Value | Volume |
| $29.38 | $29.90 | $29.28 | $56.93M | 1.920M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2798 | $29.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $29.91 | 9379 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RMD (ASX) Chart |